Malvern-based pharmaceutical company Baudax Bio has completed $5 million in stock sales, writes John George for the Philadelphia Business Journal. The proceeds made from…

Malvern-based Recro Pharma has named David Enloe its new president and CEO, writes John George for the Philadelphia Business Journal.

Enloe replaces the company…

Malvern-based Baudax Bio has signed a loan deal with Marathon Asset Management worth $50 million to support the launch of its intravenous and non…

Baudax Bio launched its new, non-opioid pain medication earlier this week, but due to the ongoing coronavirus crisis, the Malvern-based company is relying…

Malvern-based Recro Pharma saw its stock plunge by more than 34 percent after the Food and Drug Administration rejected its new drug application for…

Recro Pharma’s stock took a major hit after the FDA rejected a new drug application for the Malvern company’s non-opioid pain medication…

Malvern’s Recro Pharma has secured a line of credit worth $100 million from funds managed by Athyrium Capital Management, writes John George for the…

Recro Pharma is injecting some new prospects into its effort to alleviate surgical patients’ pain without the use of addictive opioids.

The Malvern pharmaceutical company…

Malvern’s Recro Pharma is already preparing for the potential commercial launch of its highly anticipated new drug with a $35.9 million public stock…

Recro Pharma’s latest drug test felt more like a shot of adrenaline than a sigh of relief when patients noted they were well aware…